(NASDAQ: AGRX) AGILE THERAPEUTICS's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 28.96%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.67%.
AGILE THERAPEUTICS's earnings in 2022 is -$69,535,000.On average, 1 Wall Street analyst forecast AGRX's earnings for 2022 to be -$67,223,228, with the lowest AGRX earnings forecast at -$67,223,228, and the highest AGRX earnings forecast at -$67,223,228. On average, 1 Wall Street analyst forecast AGRX's earnings for 2023 to be -$41,787,412, with the lowest AGRX earnings forecast at -$41,787,412, and the highest AGRX earnings forecast at -$41,787,412.
In 2024, AGRX is forecast to generate -$19,985,284 in earnings, with the lowest earnings forecast at -$19,985,284 and the highest earnings forecast at -$19,985,284.